News
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics
Cytovia Therapeutics has entered a research and licensing agreement with Inserm, the French National Institute of Health and Medical Research, to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma....
Scientists Develop a ‘Dual-CAR’ Targeting Two Multiple Myeloma-associated Antigens
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable successes in fighting B cell leukemias/lymphomas and numerous CAR-T's are being developed for use in multiple myeloma. While primising results have been reported with BCMA CAR T cells, responses do...
Teclistamab is an Active T Cell–Redirecting Bispecific Antibody Against BCMA for Multiple Myeloma
The success of T cell–mediated therapeutics depends, in part, on the selective expression of cell surface target epitopes to minimize the off-tissue toxicity. B-Cell Maturation Antigen (BCMA) is a protein that is selectively expressed on late-stage B cells and plasma...
BMS/Celgene Called Out by House Oversight Committee on Drug Pricing of Revlemid
House Oversight Committee hold hearings on drug Pricing. The Committee is holding two days of hearings with top executives of major drug companies to examine their pricing practices for some of the costliest drugs in the United States. The hearings, titled...
Oncopeptides Launches Melflufen Expanded Access Program in US
Oncopeptides announced today that the Melflufen open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
Featured Content
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.